Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$9.54B
Positions
136
New
11
Increased
13
Decreased
16
Sold Out
10
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $9.54B across 136 positions in their Q2 2016 SEC 13F filing (period ending 2016-06-30). The top 10 positions account for 82.7% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | INCYIncyte Corporation | $1.88B | 19.70% | +0.0% |
| 2 | SGENEURSeattle Genetics, Inc. | $1.75B | 18.32% | +0.0% |
| 3 | ABBVAbbVie Inc. | $889.87M | 9.33% | - |
| 4 | ACADACADIA Pharmaceuticals Inc. | $795.81M | 8.34% | +1.3% |
| 5 | ALXNAlexion Pharmaceuticals, Inc. | $764.00M | 8.01% | +0.0% |
| 6 | Incyte Corporation Notes 1.25% 11/15/2020 144A | $467.29M | 4.90% | - |
| 7 | Incyte Corporation Notes 0.375% 11/15/2018 144A | $431.83M | 4.53% | - |
| 8 | BMRNBioMarin Pharmaceutical Inc. | $373.94M | 3.92% | - |
| 9 | GHDXGenomic Health, Inc. | $353.95M | 3.71% | +0.1% |
| 10 | DBV Technologies S.A. | $179.72M | 1.88% | - |
| Stock | Value | Shares |
|---|---|---|
| NTLAIntellia Therapeutics, Inc. | $22.68M | 1,062,120 |
| MRUSMerus N.V. | $8.97M | 1,122,859 |
| ALDR1EURAlder BioPharmaceuticals, Inc. | $5.43M | 217,328 |
| NERVGBPMinerva Neurosciences, Inc. | $5.19M | 508,405 |
| SYRSEURSyros Pharmaceuticals, Inc. | $3.71M | 204,465 |
| GLYCEURGlycoMimetics, Inc. | $2.77M | 381,235 |
| SELBUSDSelecta Biosciences, Inc. | $2.50M | 178,950 |
| AGLEUSDAeglea BioTherapeutics, Inc. | $1.97M | 404,230 |
| SCYXSCYNEXIS, Inc. | $1.01M | 467,600 |
| Synta Pharmaceuticals Corp. | $526.00K | 2,021,728 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.